Id |
Subject |
Object |
Predicate |
Lexical cue |
T788 |
0-70 |
Sentence |
denotes |
Table 2 Compounds with inhibitory activity at MERS‐CoV and SARS‐CoV‐1 |
T789 |
71-123 |
Sentence |
denotes |
Drugs Class MERS‐CoVEC50 (µM) SARS‐CoV‐1EC50 (µM) |
T790 |
124-166 |
Sentence |
denotes |
Emetine Antibacterial agent 0.014 0.051 |
T791 |
167-211 |
Sentence |
denotes |
Chloroquine Antiparasitic agent 6.27 6.53 |
T792 |
212-263 |
Sentence |
denotes |
Hydroxychloroquine Antiparasitic agent 8.27 7.96 |
T793 |
264-308 |
Sentence |
denotes |
Mefloquine Antiparasitic agent 7.41 15.55 |
T794 |
309-353 |
Sentence |
denotes |
Amodiaquine Antiparasitic agent 6.21 1.27 |
T795 |
354-396 |
Sentence |
denotes |
Loperamide Antidiarrheal agent 4.8 5.90 |
T796 |
397-434 |
Sentence |
denotes |
Lopinavir HIV‐1 inhibitor 8.0 24.4 |
T797 |
435-474 |
Sentence |
denotes |
E‐64‐D Cathepsin inhibitor 1.27 0.76 |
T798 |
475-524 |
Sentence |
denotes |
Gemcitabine DNA metabolism inhibitor 1.21 4.95 |
T799 |
525-577 |
Sentence |
denotes |
Tamoxifen Estrogen receptor inhibitor 10.11 92.88 |
T800 |
578-631 |
Sentence |
denotes |
Toremifene Estrogen receptor inhibitor 12.91 11.96 |
T801 |
632-686 |
Sentence |
denotes |
Terconazole Sterol metabolism inhibitor 12.20 15.32 |
T802 |
687-735 |
Sentence |
denotes |
Triparanol Sterol metabolism inhibitor 5.28 ‐ |
T803 |
736-789 |
Sentence |
denotes |
Anisomycin Protein‐processing inhibitor 0.003 0.19 |
T804 |
790-846 |
Sentence |
denotes |
Cycloheximide Protein‐processing inhibitor 0.189 0.04 |
T805 |
847-904 |
Sentence |
denotes |
Homoharringtonine Protein‐processing inhibitor 0.071 ‐ |
T806 |
905-958 |
Sentence |
denotes |
Benztropine Neurotransmitter inhibitor 16.62 21.61 |
T807 |
959-1011 |
Sentence |
denotes |
Fluspirilene Neurotransmitter inhibitor 7.47 5.96 |
T808 |
1012-1063 |
Sentence |
denotes |
Thiothixene Neurotransmitter inhibitor 9.29 5.31 |
T809 |
1064-1119 |
Sentence |
denotes |
Chlorpromazine Neurotransmitter inhibitor 9.51 12.97 |
T810 |
1120-1173 |
Sentence |
denotes |
Fluphenazine Neurotransmitter inhibitor 5.86 21.43 |
T811 |
1174-1227 |
Sentence |
denotes |
Promethazine Neurotransmitter inhibitor 11.80 7.54 |
T812 |
1228-1278 |
Sentence |
denotes |
Astemizole Neurotransmitter inhibitor 4.88 5.59 |
T813 |
1279-1337 |
Sentence |
denotes |
Chlorphenoxamine Neurotransmitter inhibitor 12.64 20.03 |
T814 |
1338-1391 |
Sentence |
denotes |
Thiethylperazine Neurotransmitter inhibitor 7.86 ‐ |
T815 |
1392-1447 |
Sentence |
denotes |
Triflupromazine Neurotransmitter inhibitor 5.75 6.39 |
T816 |
1448-1501 |
Sentence |
denotes |
Clomipramine Neurotransmitter inhibitor 9.33 13.23 |
T817 |
1502-1551 |
Sentence |
denotes |
Imatinib Kinase signaling inhibitor 17.68 9.82 |
T818 |
1552-1601 |
Sentence |
denotes |
Dasatinib Kinase signaling inhibitor 5.46 2.10 |
T819 |
1602-1625 |
Sentence |
denotes |
John Wiley & Sons, Ltd. |
T820 |
1626-1750 |
Sentence |
denotes |
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. |
T821 |
1751-1933 |
Sentence |
denotes |
It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. |